Tryptamine Therapeutics (AU:TYP) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Tryptamine Therapeutics has announced successful completion of its Phase 1b trial for TRP-8803, an innovative IV-infused psilocin formulation. The study confirmed the safety and efficacy of TRP-8803 in achieving controlled psychedelic states with faster onset compared to oral psilocybin. This development paves the way for Phase 2 trials, potentially offering new therapeutic options for neuroplastic treatment.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.